Dose efficacy study of two schedules of high-dose bolus administration of interleukin 2 and interferon alpha in metastatic melanoma

Treatment of 283 Consecutive Patients With Metastatic Melanoma or Renal Cell Cancer Using High-Dose Bolus Interleukin 2

1994 • 1,070 citations

Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer Patients

1989 • 1,003 citations

Prospective Randomized Trial of High-Dose Interleukin-2 Alone or in Conjunction With Lymphokine-Activated Killer Cells for the Treatment of Patients With Advanced Cancer

1993 • 639 citations

The Neuropsychiatric Effects of Treatment with Interleukin-2 and Lymphokine-Activated Killer Cells

1987 • 456 citations

Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer.

1989 • 383 citations

Sequential chemoimmunotherapy in the treatment of metastatic melanoma.

1992 • 258 citations

Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma.

1993 • 211 citations

Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study.

1990 • 206 citations

Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma.

1993 • 181 citations

Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma.

1993 • 147 citations

Inpatient continuous-infusion interleukin-2 in 788 patients with cancer the national biotherapy study group experience

1993 • 134 citations

A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma.

1991 • 99 citations

Interferon-α and interleukin-2 in the treatment of metastatic melanoma. Comparison of two phase II trials

1993 • 93 citations

Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer.

1995 • 89 citations

Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells.

1990 • 82 citations

Phase II Study of Intravenous Bolus Recombinant Interleukin-2 in Advanced Malignant Melanoma: Southwest Oncology Group Study

1991 • 52 citations

Role of recombinant interleukin-2 in combination with interferon-alfa and chemotherapy in the treatment of advanced melanoma.

1993 • 48 citations

Disseminated Malignant Melanoma and Recombinant Interferon: Analysis of Seven Consecutive Phase II Investigations

1990 • 44 citations

Pilot Study of Interleukin-2 and Lymphokine-Activated Killer Cells Combined With Immunomodulatory Doses of Chemotherapy and Sequenced With Interferon Alfa-2a in Patients With Metastatic Melanoma and Renal Cell Carcinoma

1992 • 36 citations

Final report of a phase II study of interleukin 2 and interferon α in patients with metastatic melanoma

1995 • 20 citations

Continuous intravenous interleukin-2 infusion and subcutaneous interferon-α in metastatic renal cell carcinoma

1993 • 19 citations

Modulation of immune parameters in patients with metastatic renal-cell cancer receiving combination immunotherapy (IL-2, IFNα and autologous IL-2-activated lymphocytes)

1996 • 11 citations